Background-There is a lack of long-term data and data outside of controlled clinical trials in carotid artery stenting. Thus, we sought to evaluate the long-term effectiveness in stroke prevention by carotid artery stenting in a large number of patients in a real-world setting. Methods and Results-The present work represents an all-comer registry with a strict, prospectively designed, followup protocol, including an independent pre-and postprocedural neurological assessment. Between November 1999 and March 2015, 1000 procedures in 901 patients were consecutively performed in a single center. Mean age was 71±9 years, and symptomatic stenosis was present in 262 patients (29.1%). The population was also characterized by a high comorbidity: 289 patients (32.1%) would have been excluded according to the CREST protocol (Carotid Revascularization Endarterectomy Versus Stent Trial). The median length of follow-up was 5.5 (interquartile range, 2.6-7.9) years and complete in 93% of the patients. 
W ithin the past several years, carotid artery stenting (CAS) has been used as a less invasive alternative of stroke prevention in carotid artery stenosis versus carotid endarterectomy (CEA). 1 3 ) report an increased periprocedural death and stroke rate of CAS compared with CEA. In contrast, the CREST (Carotid Revascularization Endarterectomy versus Stent Trial) showed no significant difference between CAS and CEA in the combined end point of any periprocedural stroke, myocardial infarction, death, or postprocedural ipsilateral stroke. 4, 5 Unfortunately, all these trials have several limitations: lacking operator experience and inconsistent utilization of embolic protection devices in the European studies, underuse of dual antithrombotic therapy after CAS (EVA-3S), and heterogeneous patient selection criteria in the US studies (predominance of restenoses after surgical therapy in the SAPHHIRE trial [Stenting and Angioplasty With Protection in High Risk Patients for Endarterectomy] 6 and mixed enrollment of asymptomatic and symptomatic patients during the course of the study in CREST).
A general limitation of controlled clinical trials is constituted by the creation of an idealized patient cohort by strict inclusion and exclusion criteria at the cost of generalizability of the results. The advantage of all-comer registries is the better transferability of results to the overall population. Such registries have already shown comparable results of CAS and CEA. [7] [8] [9] [10] However, most of the previous registry data are limited with respect to the accuracy or completeness of patient surveillance, the length of follow-up, or patient number.
The purpose of the present work is to evaluate the longterm effectiveness in stroke prevention by CAS in a large number of patients and in a real-world setting with a strict, prospectively designed follow-up protocol, including an independent pre-and postprocedural neurological assessment.
Methods Patients
Our CAS program was initialized in November 1999 at a single cardiology center. For reasons of internal quality control, a computerbased database was created in which all patients with a severe carotid artery stenosis who underwent CAS or carotid artery angioplasty in our institution were prospectively included. Data of patients entered until March 2015 were utilized for the present analysis.
All patients gave informed consent for the procedure and for the collection and processing of their anonymized data. The present registry complies with the Declaration of Helsinki.
Preprocedural Assessment
Both symptomatic and asymptomatic patients were treated as from the start of the registry. Symptomatic carotid artery stenosis was defined as occurrence of a cerebrovascular event (stroke, transient ischemic attack, and amaurosis fugax) within 180 days before the procedure. Anatomic eligibility criteria were tested in every patient by duplex ultrasonography in our institution. Indication for CAS was made in the case of an at least 50% stenosis in symptomatic patients and of an at least 70% stenosis in asymptomatic patients, respectively. Duplex ultrasonography was performed again in all patients before intervention. Further imaging by contrast-enhanced computed tomography or magnetic resonance imaging was done in all cases of symptomatic stenosis and in asymptomatic patients with uncertainty in the evaluation of the carotid lesion in duplex ultrasonography. Patients were excluded when internal carotid artery occlusion, a floating thrombus, excessive tortuosity, or contraindications against the use of dual antiplatelet therapy for at least 4 weeks were present.
All patients were treated by a loading dose of clopidogrel 300 mg and of acetylsalicylic acid 500 mg at least 24 hours before the procedure when not already receiving these drugs. Postprocedurally, acetylsalicylic acid 100 mg and clopidogrel 75 mg were continued for at least 4 weeks. Thereafter, patients were advised to take acetylsalicylic acid 100 mg lifelong.
Procedure and Follow-Up
CAS was routinely performed in local anesthesia only. Heparin (bolus of 5000 IU) and atropine (1 mg) were administered in standard fashion. An activated clotting time of 250 s was mandated. An embolic protection device was used for periprocedural neuroprotection whenever anatomically possible.
All procedures were performed by either H.M. or M.S., with H.M. attending every implantation as senior interventionalist. In addition to CAS, patients received optimal medical treatment including statins, antidiabetic drugs, and adequate blood pressure control with target goals according to current guidelines, eg, low-density lipoprotein <100 mg/dL, glycosilated hemoglobin A1c <7%, and systolic blood pressure <140 mm Hg.
A detailed neurological assessment was performed by an independent neurologist in every patient within 24 hours before and after the procedure. The neurological evaluation included the National Institutes of Health Stroke Scale and the modified Rankin Scale. Routine creatine kinase tests for detection of myocardial infarction were performed the day after the procedure. In case of positive creatine kinase, chest pain or pathological ECG changes indicating myocardial ischemia, further testing was initiated, including a troponin assay since 2002.
Follow-up was performed routinely on day 30 after stent implantation by means of a structured telephone interview. Subsequently, a written standardized questionnaire was to be filled out by all patients on a yearly basis. In the case of adverse events, patient documents were requested and carefully analyzed. Routine duplex ultrasonography follow-up was not performed in our institution, but by the referring physician, and the reports were regularly requested. A peak systolic velocity of >200 cm/s was considered as proof of manifest restenosis.
End Points
Primary end point was the 30-day composite of death, any stroke, or myocardial infarction (major adverse cardiac or cerebrovascular event [MACCE]) plus long-term (beyond 30 days) ipsilateral stroke. Secondary end point was the composite of any periprocedural stroke plus long-term (beyond 30 days) ipsilateral stroke (stroke end point).
Stroke was defined as new or worsened focal neurological symptoms lasting >24 hours. The stroke was considered major when lasting at least 30 days and if a National Institutes of Health Stroke Scale of ≥4 points and a modified Rankin Scale score of ≥3 was present. Myocardial infarction was defined as elevation of cardiac enzymes (creatinekinase/CK isoenzymes M and B) to more than twice the upper limit of the normal laboratory value or a significant rise of troponin I in addition to pathological ECG changes or typical chest pain lasting longer than 30 minutes.
Statistical Analysis
Values are expressed as numbers and percentages or means with SD. Medians with quartiles were calculated if the Kolmogoroff-Smirnov test showed a non-normal distribution of continuous variables. For comparison of the data, the χ 2 or Fisher exact test was used for categorical variables and the Mann-Whitney-Wilcoxon or Student t test was applied for continuous variables.
For the 30-day outcome also patients who only underwent angiography without an intervention were entered on an intentionto-treat basis. In patients with several procedures, every single procedure was counted for the 30-day outcome. Therefore, the 30-day collective is in line with the total number of interventions. About the calculation of long-term events, only patients-not procedures-were included, irrespective of the number of reinterventions or bilateral procedures performed. Long-term outcomes were compared using the log-rank test.
A multivariable analysis using Cox regression with forward selection was performed for predictor analysis of the primary end point. Variables entered into the model were age, sex, symptomatic status, arterial hypertension, hypercholesterinaemia, coronary heart disease, diabetes mellitus, atrial fibrillation, heart failure, renal failure, contralateral carotid artery occlusion, and stent length of ≥40 mm.
All P values were calculated by 2-tailed tests, and statistical significance was defined at P<0.05. Analysis was performed by SPSS software, version 22 (SPSS, Chicago, IL).
WHAT IS KNOWN
• Long-term data on carotid artery stenting outside of controlled clinical trials are lacking.
WHAT THE STUDY ADDS
• The present analysis shows that carotid artery stenting performed in clinical practice provides similar long-term effectiveness in stroke prevention compared with randomized trials.
• A careful risk/benefit calculation is nevertheless needed, particularly in patients not eligible for randomized trials because of their increased periprocedural stroke risk. Figure 1 illustrates the course of our CAS program. Altogether, 1000 procedures were performed in 901 patients from November 1999 to March 2015.
Results

Baseline Characteristics
Mean patients' age was 71±9 years, with 36.1% aged ≥75 years and 17.5% aged ≥80 years. Symptomatic stenosis was present in 262 patients (29.1%). All baseline characteristics are displayed in Table 1 . Sixty-five patients (7.2%) presented with a restenosis after previous CEA at baseline. Table I in the Data Supplement shows the proportion of patients who met exclusion criteria for the CREST trial. In total, 32.1% would have been excluded from the CREST trial, whereas 40.5% fulfilled the high-risk criteria of the SAPHHIRE study. 6 
Procedural Outcome
Procedural success was achieved in 98.1% (954/972) of the cases. A cerebral protection device was used in 97.8% (941/972), the type of embolic protection and remaining procedural details are shown in Table 2 .
The 30-day MACCE rate was 5.0% (50/1000) with a trend toward a higher risk for MACCE in symptomatic patients (7.7% versus 4.0%; P=0.06; Table 3 ). Moreover, symptomatic patients bore a significantly higher risk than asymptomatic patients for the composite of death and major stroke (5.6% versus 1.7%; P=0.001) and major stroke alone (3.7% versus 0.8%; P=0.008). The risk for MACCE, death, and major stroke significantly changed when stratified for the CREST exclusion criteria (Figure 2A ). The rate of MACCE in those who would be eligible for CREST was 4.3% among symptomatic patients and 3.6% in asymptomatic patients ( Figure 2B) . Also, those patients who were high risk according to the SAPHHIRE criteria had an increased risk for MACCE (7.0% versus 3.8%; P=0.021).
The cause of strokes was ischemic in 36 patients and hemorrhagic in 2 patients. In total, 14 patients died during the 30-day period. Causes of the death are listed in Table II in the Data Supplement.
Long-Term Outcome
Seven percent of the patients (64/878) were lost to followup during the course of the registry. The median length of follow-up was 5.5 (interquartile range, 2.6-7.9) years (4829 patient-year), and 114 patients (13.0%) reached the 10-year follow-up. A total of 290 patients (33.0%) died within the observational period. The cause of death could be established in 237 patients (82%), with cardiac diseases, malignancies, and infections being the most frequent (Table 4) .
The Kaplan-Meier estimated 10-year rates for the primary end point and stroke end point were 6.9% and 5.6%, respectively. After the 30-day period an ipsilateral stroke occurred in 8 patients (1.1%), yielding an annual risk for ipsilateral stroke of 0.6% (0.8% in symptomatic and 0.5% in asymptomatic patients) when including the periprocedural period. Symptomatic patients had a higher rate of incidence of the primary end point compared with asymptomatic patients (Figure 3A) , whereas no significant difference was noted between symptomatic and asymptomatic patients with regard to the stroke end point ( Figure 3B ). Patients who would have been excluded from CREST were at an increased risk for both the primary end point ( Figure 3C ) and stroke end point ( Figure 3D ) in comparison to those who were eligible for CREST. In CREST eligible patients, the risk for the primary end point was 5.0% in symptomatic and 4.8% in asymptomatic patients. Those who were considered high risk for CEA according to SAPPHIRE had a higher estimated risk for the primary end point (9.4% versus 5.4%; P log rank=0.047). The rate for the stroke end point was not significantly different (6.9 versus 4.8%; P=0.28). In multivariable analysis, age ≥75 years, diabetes mellitus, heart failure, and stent length of ≥40 mm were found to be independent predictors for the primary end point (Table 5) . Duplex ultrasonography was performed on 852 of 901 patients (95%) at a median follow-up time of 3.1 (interquartile range, 0.5-6.0) years. The estimated risk for the first recurrence of stenosis was 4.3% at 10 years (annual rate of 0.4%). Two of the 19 patients with restenosis had a stroke. A reintervention was performed in 15 of those 19 patients.
Life expectancies in Germany for those who are alive at the ages of 55, 65, and 75 years are shown in Figure I in the Data 
Discussion
The population in the present analysis is characterized by high comorbidity and an increased procedural stroke risk. A substantial number of patients would have been excluded from the CREST trial and fulfilled high-risk criteria according to SAPHHIRE. This illustrates to which extent controlled clinical trials may under-represent groups of patients in whom the investigated technique is used in daily clinical practice.
Procedural Outcome
With a 30-day MACCE rate of 5.0% (7.7% in symptomatic and 4.0% in asymptomatic patients), our procedural risk is similar to that of previous randomized trials (range from 5.2% to 9.6%; except for CREST only death and stroke were recorded as primary end point) 2-4,11 and prospective registries (range from 6.2% to 13.0% in symptomatic patients and from 3.3% to 6.8% in asymptomatic patients).
10,12-15 About asymptomatic patients, our MACCE rate was slightly higher than in the recently published ACT I trial (Randomized Trial of Stent Versus Surgery for Asymptomatic Carotid Stenosis) (30-day MACCE rate of 3.3% for CAS and 2.6% for CEA). 16 Some high-volume centers report lower event rates in their real-world populations of symptomatic and asymptomatic patients (range from 1.7% to 4.7%). 7, 8, [17] [18] [19] [20] However, 3 major issues need to be considered when comparing the current results with older reports. First, a strict, independent neurological assessment before and after the procedure was not mandatory in previous trials and even less so in registries. Second, it must be noted that some deaths within the 30-day period in the present analysis were unrelated to the procedure: two cases occurred during coronary artery bypass graft surgery and 1 case was because of severe aortic stenosis scheduled for surgery within 30 days after CAS. In fact, the approach of performing carotid revascularization in asymptomatic patients before cardiac surgery was abandoned during the course of the registry because guidelines changed and routine carotid revascularization before coronary artery bypass graft is now no longer recommended. 21 Third, the proportion of comorbidities was higher than in many other reports. This interpretation is underscored by a comparable event rate in high-risk patients of our registry and of the SAPHHIRE trial, using the same criteria of defining risk. 6 Furthermore, those who met the CREST exclusion criteria had a significantly higher risk for MACCE, death, and major stroke. Compared with the CAS arm of the CREST trial, our CREST eligible patients had a comparable MACCE rate (3.8% versus 5.2%).
The increased risk for major stroke in symptomatic patients seems to be predominantly influenced by age, as the risk decreased to 1.4% in symptomatic and 0.5% in asymptomatic patients, respectively, when assessing only patients <75 years. In accordance with this finding, the multivariable analysis found age as an independent predictor for the primary end point. A possible explanation for this phenomenon may be the more frequently encountered unfavorable anatomy among older patients. 22 Severe tortuosity and heavy calcification of supra-aortic arteries potentiate the risk for embolism by catheter and wire manipulation, particularly in symptomatic patients who have already proven vulnerability of their atherosclerotic lesions. New stent designs incorporating an inner mesh with pore sizes down to below 200 µm might allow at least some further reduction of lesion-derived microemboli. 
Long-Term Outcome
The rate of occurrence of the primary end point (procedural MACCE and long-term ipsilateral stroke) in the present analysis (6.9% overall, 9.9% symptomatic, and 5.7% asymptomatic) is comparable to that of large randomized trials (range from 7.2% to 11.8% in the CAS group and from 6.8% to 8.8% in the CEA group). 4, [24] [25] [26] However, a direct comparison is difficult. All other randomized trials with long-term follow-up, except for CREST, were conducted in only symptomatic patients, and the risk profile of the respective populations was heterogeneous. When only considering symptomatic patients, our event rate is between that obtained by CAS and CEA in those trials. After adjustment for risk factors by evaluating only CREST eligible patients, the risk declined to 5.0% in symptomatic and 4.8% in asymptomatic patients (overall 4.9%). The overall risk for the primary end point is also comparable with results from other high-volume centers, despite their generally shorter long-term follow-up. 8, [18] [19] [20] Furthermore, we were able to prevent neurological complications effectively: the observed annual risk for ipsilateral stroke (including the periprocedural period) of 0.6% in the overall cohort compares favorably with the 1.1% of the 10-year CREST data. 5 Our data also support the growing body of evidence that CAS results after the 30-day interval are durable; the flat course of the Kaplan-Meier curves signifying freedom from ipsilateral stroke. A similar development has been indicated by the CREST investigators in their 10-year-follow-up analysis. 5 Other than in symptomatic patients, the optimal therapy in patients with asymptomatic stenosis remains under debate. This is largely because noninvasive medical therapy has improved over time, particularly the increasing use of statins. Their benefit was shown in a subgroup analysis of the ACST-1 (Asymptomtic Carotid Surgery Trial) with patients on lipid-lowering drugs. 27 Current optimal medical therapy might reduce the annual stroke rate to even <1% per year. 28 However, studies reporting stroke rates ≈0.5% per year analyzed patients with only moderately severe stenoses of ≈50% to 60%. 29 The steady decline of the survival curves in the present population ( Figure I in the Data Supplement) underlines the importance of a careful risk/benefit calculation, periprocedural complication rate, and calculated life expectancy being the major determinants.
Similar to CREST, EVA-3S, and high-volume singlecenter reports, 8, 18 in the present analysis, the rate of restenosis after CAS remained relatively low and at the same level as after CEA in randomized trials. Finally, it has to be emphasized that only 2 of the 19 of our patients with restenosis had stroke. Accordingly, we state that recurrent stenosis does not hamper the benefit of CAS in long-term stroke prevention in our experience. Kaplan-Meier 10-y outcome estimates. Symptomatic patients had a higher rate of the primary end point than asymptomatic patients after an observational period of 10 y (9.9% vs 5.7%). This difference was mainly driven by an increased number of acute complications (A). The same trend was seen about the stroke end point (7.8% vs 4.7%). However, the difference did not reach statistical significance (B). CREST ineligible patients had a significantly higher risk than CREST suitable patients for both, primary end point (11.4% vs 4.9%; C) and stroke end point (8.6% vs 4.2%; D). Long-Term Data of Carotid Artery Stenting
Limitations
Several limitations have to be noted. (1) Long-term follow-up was performed by questionnaire. Hence, some neurological complications (eg, minor strokes) might have been missed. Although the clinical relevance of an event not noticed by the patient is doubtful, this shortcoming remains. (2) The postprocedural duplex ultrasonography examination was mostly not performed in our institution, but by the referring physician. Therefore, a certain interobserver variability and the use of different criteria for assessment of severity of restenosis must be expected. However, every patient with suspected restenosis of ≥50% underwent a duplex ultrasonography control at our site. (3) In the absence of a randomized control group, definite comparison to CEA or medical therapy regimes cannot be made. (4) As the present data are gathered in a single-center experience, the results cannot be generalized in a simple manner.
Conclusion
The present analysis emphasizes that CAS can be performed with high procedural success and reasonable procedural safety in a high-volume center with experienced interventionalists, utilization of appropriate devices, and under consequent embolic protection. Concomitant guideline-oriented drug therapy provides adequate long-term effectiveness in stroke prevention in both symptomatic and asymptomatic patients. The risk profile of patients in daily clinical practice differs from that in randomized controlled trials and has a strong impact on the outcome after CAS. Therefore, patient characteristics-particularly age, diabetes mellitus, and CREST eligibility-need to be considered before any CAS procedure is performed. 
